Last $1.48 USD
Change Today 0.00 / 0.00%
Volume 0.0
GEDSF On Other Exchanges
Symbol
Exchange
OTC US
OTC US
OTC US
Frankfurt
As of 4:30 PM 06/25/13 All times are local (Market data is delayed by at least 15 minutes).

richter gedeon -spons gdr (GEDSF) Snapshot

Open
--
Previous Close
$1.48
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
186.4M
EX-Date
06/4/14
P/E TM
--
Dividend
$0.25
Dividend Yield
17.06%
Current Stock Chart for RICHTER GEDEON -SPONS GDR (GEDSF)

Related News

No related news articles were found.

richter gedeon -spons gdr (GEDSF) Related Businessweek News

No Related Businessweek News Found

richter gedeon -spons gdr (GEDSF) Details

Chemical Works of Gedeon Richter Plc is engaged in the research, development, manufacture, and marketing of human finished drugs, active substances, and intermediates in Hungary and internationally. It offers gynecological products, such as contraceptive and emergency contraceptive pills; hormone replacement therapy treatments; disinfectant products and other preparations for gynaecological use; and antifungal agents for acute and chronic recurring vaginal fungal infections. The company also provides cardiovascular products, such as ACE-inhibitor products to lower blood pressure and products for reducing cholesterol; gastroenterological products that include solutions for gastric and duodenal ulcers, as well as other syndromes related to stomach acid; and over the counter medicines. In addition, it offers central nervous system products, including anti-depressant product; products for chronic cerebral circulatory disorders and chronic cerebrovascular diseases, as well as products in the pre-clinical and clinical trial phases for anxiety, schizophrenia, and chronic pain; and neurological agents consisting of anaesthetics, anxiolytics, tranquilisers, antiepileptic drugs, alleviating neuropathic pain products, and interferon medications for the treatment of multiple sclerosis. Further, the company provides antibiotics to treat inflammation of ears, sinusitis, pneumonia, and dermatological syndromes; antimicotics for skin and nail fungal diseases; and non-steroidal anti-inflammatory drugs, muscle relaxants, and anti-osteoporosis products. Additionally, it is involved in biotechnological manufacturing and research, transportation and carriage, quality control, asset management, and pharmaceutical trading and retail activities; and provision of catering, car rental, and engineering services. Chemical Works of Gedeon Richter Plc was founded in 1901 and is based in Budapest, Hungary.

11,767 Employees
Last Reported Date: 05/7/14
Founded in 1901

richter gedeon -spons gdr (GEDSF) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

richter gedeon -spons gdr (GEDSF) Key Developments

Chemical Works of Gedeon Richter Plc Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2014

Chemical Works of Gedeon Richter Plc announced unaudited consolidated earnings results for the first quarter ended March 31, 2014. For the quarter, the company reported total revenues of HUF 88,527 million compared to HUF 85,844 million a year ago. Profit from operations was HUF 10,264 million compared to HUF 15,217 million a year ago. Profit before income tax was HUF 9,628 million compared to HUF 20,023 million a year ago. Net income attributable to owners of the parent company was HUF 9,342 million compared to HUF 19,050 million a year ago. EBITDA was HUF 17,890 million compared to HUF 22,384 million a year ago. Basic and diluted EPS was HUF 50 compared to HUF 102 a year ago. Capital expenditure for the Group including payments for intangible assets totalled HUF 5,469 million compared to HUF 3,155 million reported for the three months to March 2013. Capital expenditure linked to the development of biotechnology R&D facilities and manufacturing capacity in Hungary was HUF 192 million in the first quarter 2014. Net cash flow from operating activities was HUF 15,471 million compared to HUF 19,137 million a year ago. Payments for property, plant and equipment were HUF 4,416 million compared to HUF 2,486 million a year ago. Payments for intangible assets were HUF 1,053 million compared to HUF 669 million a year ago.

Chemical WKS Of Richter Gedeon Plc Announces Earnings Results for the Full Year Ended December 31, 2013

Chemical WKS Of Richter Gedeon Plc announced earnings results for the full year ended December 31, 2013. For the period, the company reported total revenues of HUF 351,424 million compared with HUF 326,702 million for the same period a year ago. Profit from operations was HUF 45,569 million compared with HUF 48,696 million for the same period a year ago. Profit before tax was HUF 43,640 million compared with HUF 49,896 million for the same period a year ago. Profit attributable to owners of the parent was HUF 42,766 million or HUF 229 per diluted share compared with HUF 49,240 million or HUF 264 per diluted share for the same period a year ago. Net cash flow from operating activities was HUF 74,008 million compared with HUF 61,834 million for the same period a year ago. Payments for property, pant and equipments was HUF 25,343 million compared with HUF 23,803 million for the same period a year ago. Payments for intangible assets was HUF 8,304 million compared with HUF 5,874 million for the same period a year ago.

Richter Provides Consolidated Revenue Guidance for the Fiscal Year 2014

Richter provided consolidated revenue guidance for the fiscal year 2014. The company expected its revenue in Ukraine to drop significantly in 2014. The expected fall in sales in Ukraine would reduce the company's consolidated revenue as well.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GEDSF:US $1.48 USD 0.00

GEDSF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BTG PLC 622.00 GBp -1.50
Hikma Pharmaceuticals PLC 1,791 GBp +4.00
Krka dd Novo mesto €63.75 EUR +0.25
Ranbaxy Laboratories Ltd 561.15 INR -2.10
Stada Arzneimittel AG €32.16 EUR +0.375
View Industry Companies
 

Industry Analysis

GEDSF

Industry Average

Valuation GEDSF Industry Range
Price/Earnings 22.3x
Price/Sales 2.1x
Price/Book 1.3x
Price/Cash Flow 22.3x
TEV/Sales 1.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RICHTER GEDEON -SPONS GDR, please visit www.richter.hu. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.